ClinicalTrials.gg
Active, not recruitingNCT07207408Updated Oct 5, 2026

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

A Phase 2 interventional study of rF1V-1018 and rF1V-1018 in Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis, sponsored by Dynavax Technologies Corporation. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 2, Interventional, and Prevention

Updated Oct 5, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine

Read the detailed description

This dose-finding study will evaluate the immunogenicity, safety, and tolerability of multiple doses and regimens of rF1V-1018 vaccine in healthy adults. Immunogenicity blood samples will be drawn at several timepoints during the study. Participants will return to the clinic for periodic visits for study specific evaluations including evaluation of immunogenicity and safety. Safety assessments will be done at regular intervals through the end of the trial.

Six dose regimens will be tested in Part 1 of the study. Up to two dose regimens from Part 1 will be chosen for Part 2 of the study.

02

Conditions studied

  • Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
03

In context

Lead sponsor

Dynavax Technologies Corporation is the lead sponsor of 25 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

First submitted before Dynavax Technologies Corporation became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults 18 to 55 years of age
  2. Healthy participants or participants with stable pre-existing medical conditions Pre-existing stable medical condition means a participant who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.
  3. Able to comply with the protocol schedule and procedures
  4. Able and willing to provide written
  5. If female of and heterosexually active, has practiced adequate for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adequate contraception through three months following the final trial injection

A premenopausal woman who has at least one of the following is considered not of childbearing potential:

  1. Documented hysterectomy
  2. Documented bilateral salpingectomy
  3. Documented bilateral oophorectomy
  4. Documented and current bilateral tubal ligation or occlusion

Exclusion criteria

Exclusion Criteria:

  1. A history of plague disease or have previously received any plague vaccine
  2. Active tuberculosis or other systemic infectious process
  3. History of (HIV), (HBV) or (HCV) infection, or positive test for antibody to HIV, HBV, or HCV
  4. History of disorder
  5. History of sensitivity to any component of trial vaccines
  6. ≥ 30 kg/m2
  7. Has received the following prior to any trial injection:

    a) ≤ 14 days: i) Any licensed or authorized inactivated vaccines (including vaccines containing mRNA or CpG) b) ≤ 28 days: i) Any ii) Any medicinal agent c) ≤ 90 days: i) Chronic administration (defined as more than 14 consecutive days in total) of or other immune-modifying drugs during the period starting 90 days prior to the first trial vaccine administration or planned administration during the trial period. (For , this will mean prednisone ≥20 mg/day, or equivalent). Inhaled, topical, and intraarticular steroids are allowed.

    ii) Granulocyte or granulocyte-macrophage colony stimulating factor iii) Immunoglobulins or any blood products (receipt of certain monoclonal antibodies may on a case-by-case basis be non-exclusionary if approved via consultation with Sponsor Medical Monitor) iv) Antisense oligonucleotides v) Drugs/investigational agents with very long half-lives (defined as ≥ 60 days) (eg, radioactive iodine, amiodarone, liraglutide, nirsevimab, teplizumab, evinacumab, and obinutuzumab) vi) Infusion of blood products d) At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells

  8. If female is pregnant (known before or established at the time of screening), breastfeeding, or planning breastfeeding or a pregnancy
  9. Is undergoing chemotherapy or expected to receive chemotherapy during the trial period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
  10. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  11. Oral temperature ≥ 38°C (≥ 100.4°F) at the time of vaccine administration
  12. History of acute myocardial infarction (AMI) or documented coronary artery disease (CAD)

    -

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Part 1 Arm 1

    Biological: rF1V-1018

  • Experimental
    Part 1 Arm 2

    Biological: rF1V-1018

  • Experimental
    Part 1 and Part 2: Arm 3

    This Part 1 arm was selected for Part 2.

    Biological: rF1V-1018

  • Experimental
    Part 1 and Part 2: Arm 4

    This Part 1 arm was selected for Part 2.

    Biological: rF1V-1018

  • Experimental
    Part 1 Arm 5

    Biological: rF1V-1018

  • Experimental
    Part 1 Arm 6

    Biological: rF1V-1018

Interventions

  • BiologicalrF1V-1018

    Regimen 1

  • BiologicalrF1V-1018

    Regimen 2

  • BiologicalrF1V-1018

    Regimen 3

  • BiologicalrF1V-1018

    Regimen 4

  • BiologicalrF1V-1018

    Regimen 5

  • BiologicalrF1V-1018

    Regimen 6

06

What researchers measure

Primary outcomes

  1. Anti-rF1V antibody level

    Time frame: 4 weeks after final study vaccine

  2. Evaluate safety of rF1V-1018

    Evaluate adverse events

    Time frame: injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine

07

Study locations

4 sites
  • 103
    Miami, Florida 33172, United States
  • AMR- El Dorado
    El Dorado, Kansas 67042, United States
  • AMR- Las Vegas
    Las Vegas, Nevada 889119, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 6, 2025
StartActual
Sep 11, 2025
Primary completionEst.
Jan 29, 2027
CompletionEst.
Aug 31, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Active, not recruiting
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07207408
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Sep 11, 2025
Primary completion
Jan 29, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion